# 64Cu-SAR-bisPSMA for Identification of Participants With Recurrence of Prostate Cancer (COBRA)

> **NCT05249127** · PHASE1,PHASE2 · COMPLETED · sponsor: **Clarity Pharmaceuticals Ltd** · enrollment: 52 (actual)

## Conditions studied

- Biochemical Recurrence of Malignant Neoplasm of Prostate

## Interventions

- **DRUG:** 64Cu-SAR-bisPSMA

## Key facts

- **NCT ID:** NCT05249127
- **Lead sponsor:** Clarity Pharmaceuticals Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-11
- **Primary completion:** 2023-08-08
- **Final completion:** 2023-08-08
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2024-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05249127

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05249127, "64Cu-SAR-bisPSMA for Identification of Participants With Recurrence of Prostate Cancer (COBRA)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05249127. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*